Molecular Biomarkers for Breast Cancer Prognosis: Coexpression of c-erbB-2 and p53
- 1 May 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 233 (5) , 630-638
Abstract
To assess the prognostic significance of molecular biomarkers, particularly c-erbB-2 and p53, through study of prospective clinical data and archival breast cancer tissues for women accrued to the Alabama Breast Cancer Project. Defining molecular abnormalities in breast cancer is an important strategy for early detection, assessment of prognosis, and treatment selection. Evidence is strong that selective biomarkers, including c-erbB-2 and p53, have prognostic significance in breast cancer. Few studies have analyzed the prognostic significance of coexpression of biomarkers. Study patients were those accrued to the Alabama Breast Cancer Project (1975–1978) who had archival breast cancer tissues available for analysis. Criteria for entrance into the Alabama Breast Cancer Project were T1–3 breast cancer with M0 status. Age, nodal status, and histologic grade were also documented. Patients were randomized to radical versus modified radical mastectomy, and node-positive patients were also randomized to adjuvant chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil [CMF]) versus melphalan. Archival breast cancer tissues were studied for c-erbB-2, TGF-α, p53, cathepsin D, bcl-2, and estrogen and progesterone receptor expression using immunohistochemistry. Survival curves were developed using the Kaplan-Meier method. Univariate analysis was performed using the log-rank test, multivariate analysis using a rank regression model. Three hundred eleven patients were accrued to the Alabama Breast Cancer Project, and paraffin-embedded breast cancer tissues for 90 patients were available for immunohistochemical analysis of molecular biomarkers. Univariate analysis showed nodal status, c-erbB-2 expression, and p53 expression to have prognostic significance. Coexpression of c-erbB-2 and p53 was also found to have prognostic significance by the log-rank test. Multivariate analysis showed T stage, nodal status, c-erbB-2 expression, and p53 expression to have independent prognostic significance. These data suggest that c-erbB-2 and p53 expression in breast cancer have prognostic significance. After median follow-up of 16 years, coexpression of c-erbB-2 and p53 may have more prognostic significance than traditional prognostic factors such as T stage and nodal status. Prospective study of large numbers of patients with breast cancer is encouraged to validate these findings.Keywords
This publication has 48 references indexed in Scilit:
- p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breastEuropean Journal of Cancer, 1997
- No Additive Impact on Patient Survival of the Double Alteration of p53 and c-erbB-2 in Breast CarcinomasJNCI: Journal of the National Cancer Institute, 1996
- p53 protein expression and nuclear DNA content in breast intraductal proliferationsThe Journal of Pathology, 1995
- Oncogene Protein Co-Expression Value of Ha-ras, c-myc, c-fos, and p53 as Prognostic Discriminants for Breast CarcinomaAnnals of Surgery, 1995
- Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patientsJournal of Cancer Research and Clinical Oncology, 1994
- P-glycoprotein, HER-2/neu, and Mutant p53 Expression in Human Gynecologic TumorsJNCI: Journal of the National Cancer Institute, 1994
- p53 immunostaining in benign breast diseaseThe Lancet, 1991
- Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitroInternational Journal of Cancer, 1990
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988
- Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogeneCell, 1988